A Phase 1/2 interventional study of Posiphen and Placebo in Alzheimer's Disease, sponsored by Annovis Bio Inc.. Completed at 6 sites in United States. Open to participants aged 55 Years to 89 Years. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by Annovis Bio Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 1,330th largest by enrollment of the 1,609 interventional ones that give a count, is one of 69 that started in 2017, is one of 67 in phase 1/2, and was the 818th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,940 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 69 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,609 interventional studies, 160 across the 309 observational. Of the 1,378 that completed or were terminated, 590 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,940 have an industry lead sponsor. The 10 most frequent:
Annovis Bio Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Annovis Bio Inc. has 6 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
165 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 165 to your calendar (.ics) → With an account.
Among the 1,940 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the safety and pharmacological effects of 3 different doses of Posiphen® when compared to a placebo, in adult male and female patients with early Alzheimer's disease (AD).
Posiphen®, which was discovered by the US National Institute on Aging (NIA) is a small, orally active, experimental drug that specifically inhibits the synthesis of amyloid precursor protein (APP), Tau and α-Synuclein. It is distinct from other Alzheimer's disease drugs currently in development, because it inhibits the formation of several toxic proteins, rather than removing individual toxic protein after they are produced. Posiphen has potential utility as a disease modifying treatment for AD. The present study will confirm the pharmacokinetics (PK) of Posiphen and its metabolites in plasma and cerebral spinal fluid (CSF). It will also measure the effects of a 23-25 day treatment period with Posiphen on the CSF and plasma levels of a number of biomarkers, inflammatory factors and control proteins. It will also expand the safety data in humans by extending the treatment period from 10 days to a treatment period from 23-25 days. In addition, this study will measure concentrations of various soluble biomarkers in CSF and use the SILK™ assay methods to directly measure the effect of Posiphen on the fractional synthesis rate of Aβ40 in CSF, which will help guide the further development of Posiphen and determine the feasibility of SILK™ in a multicenter trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study drug Posiphen dosage of 60mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
Drug: Posiphen
The study drug Posiphen dosage of 120mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
Drug: Posiphen
The study drug Posiphen dosage of 180mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
Drug: Posiphen
The Placebo comparator is to be taken orally in divided doses, three times per day for a total 23-25 days.
Drug: Placebo
oral solid dosage form capsule
oral solid dosage form capsule
Safety and Tolerability of Multiple Ascending Doses of Posiphen: Reports of Adverse Events or Study Discontinuations
Number of adverse events or study discontinuations, broken down by dose arm (i.e. Low vs. Medium vs. High vs. Placebo), and further broken down by relatedness to Posiphen (Definitely Related, Probably Related, Possibly Related, Unlikely Related, Unrelated)
Time frame: Up to 25 days
The Levels of Posiphen and Its Metabolites Will be Determined in Plasma
Mean plasma concentrations of levels of posiphen tartrate, N1 desmethyl posiphen, and N8 desmethyl Posiphen metabolite were determined for each of the three dose cohorts (Low Dose, Medium Dose, High Dose) by a protein precipitation extraction method using a high performance liquid chromatographic mass spectrometric detection method, with a linear weighted regression to determine their concentrations.
Time frame: The confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window. Plasma was collected at 0, 2, 4, 8, 12, 16, 20, and 24hrs during the confinement visit.
The Levels of Posiphen and Its Metabolites Will be Determined in Cerebrospinal Fluid (CSF)
Mean CSF concentrations of levels of posiphen tartrate, N1 desmethyl posiphen, and N8 desmethyl Posiphen metabolite were determined for each of the three dose cohorts (Low Dose, Medium Dose, High Dose) by a protein precipitation extraction method using a high performance liquid chromatographic mass spectrometric detection method, with a linear weighted regression to determine the concentrations.
Time frame: The confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window. Plasma was collected at 0, 2, 4, 8, 12, 16, 20, and 24hrs during the confinement visit.
Fractional Synthesis Rate of Aβ40 in CSF Using the SILK™ Technique With Multiple Doses of Posiphen
The fractional synthesis rate (FSR) of Aβ40 was measured in the CSF using the SILK™ technique. FSR is a measure of the rate of Aβ synthesis in the brain. During 13C6-leucine infusion, 13C6-leucine is incorporated into newly synthesized proteins throughout the body, including the brain, in proportion to the available 13C6-leucine. This FSR is calculated as the rate of change of the ratio of 13C6-leucine-labeled Aβ proteins to unlabeled Aβ proteins in the lumbar CSF between 6 to 16 hours, normalized to the ratio of labeled to unlabeled leucine amino acid in plasma. It is reported as a fraction of 13C6-leucine-labeled to unlabeled Aβ proteins per hour. The ratio of Aβ in CSF containing 13C6-leucine to that containing unlabeled leucine is measured using mass spectrometry.
Time frame: The confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window. CSF was collected between 6 and 16hrs during the confinement visit.
Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate Rates of Enrollment
Feasibility of CSF Catheter Study with SILK™ Technology was determined by comparing the total number of participants enrolled, randomized and treated with study drug in the trial to the total number of participants who completed the CSF Catheter Study across all participating sites.
Time frame: Up to 25 days
Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate %CSF Samples With Enough Volume for Testing
The % of cerebrospinal fluid samples with sufficient volume for testing will be determined across study participants during the SILK sampling procedure
Time frame: Up to 25 days
Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate Research Satisfaction
Research satisfaction will be evaluated by qualitative response to 14 questions asked to participants about their experience with the study procedures. Responses will be grouped and reported by common themes
Time frame: Up to 25 days
Pharmacodynamic and PK-PD Effects on CSF Alzheimer's Disease Biomarkers
Aβ38, Aβ40, Aβ42, sAPPα, sAPPβ, and T-Tau were sampled at Screening and at the start of the confinement visit. Results of these measures were reported as a least square means, calculated as the change between the measured values at the start of the confinement visit and Screening in ng/mL.
Time frame: CSF was sampled at Screening and at the start of the confinement visit, which occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window.
Assessment of Mental Status Effects
The short-term effects of Posiphen on mental status will be measured using the Mini-Mental State Examination (MMSE). The MMSE is a brief, global cognitive measure that includes orientation, memory, attention, concentration, naming, writing, repetition, comprehension, and construction. The total score ranges from 0 (worst) to 30 (best performance). Results of the MMSE for this trial were reported as a raw change score, calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) and where negative values are worse and positive values are better.
Time frame: MMSE was administered at Baseline and at the Pre-Confinement Visit 1-3 days prior to the Confinement Visit. This confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window.
Assessment of Neuropsychiatric Effects
The Neuropsychiatric Inventory (NPI) was used to measure the frequency and severity of neuropsychiatric symptoms. On this scale frequency ratings range from 0 (no symptoms) to 4 (very frequently, once or more per day or continuously). Severity ratings range from 0 (no severity) to 3 (severe). The score for each of 12 symptoms measured in the scale is the product of severity and frequency within that symptom. The total score for the NPI is the sum of all 12 symptom item scores, for a highest possible total score of 144 in individuals with maximal symptoms, and a lowest possible total score of zero (0) in fully asymptomatic individuals. Lower scores are better and higher scores indicate more neuropsychiatric symptoms. Results are calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) with negative scores being better and positive scores being worse.
Time frame: NPI was administered at Baseline and at the Pre-Confinement Visit 1-3 days prior to the Confinement Visit. This confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, while also allowing a +/- 2-day visit window.
Assessment of Cognitive Effects
The short-term effects of Posiphen on cognition were measured using the The Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12). The ADAS-Cog is a structured scale that evaluates memory (word recall, word recognition), reasoning, language (naming, comprehension), orientation, ideational praxis and constructional praxis. The test is scored in terms of errors, with higher scores reflecting poorer performance and greater impairment. Total ADAS-Cog12 scores can range from 0 to 80, with lower scores being better and higher scores being worse. Results of the ADAS-Cog12 for this trial are reported as a raw change score, calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) with negative scores being better and positive scores being worse.
Time frame: ADAS-Cog12 was administered at Baseline and at the Pre-Confinement Visit 1-3 days prior to the Confinement Visit. This confinement visit occurred following 21-23 days of treatment with either Posiphen or placebo, also allowing a +/- 2-day visit window.
| Milestone | Low Dose | Medium Dose | High Dose | Placebo |
|---|---|---|---|---|
| Started | 5 | 5 | 1 | 7 |
| Completed | 4 | 5 | 1 | 5 |
| Not completed | 1 | 0 | 0 | 2 |
Number of adverse events or study discontinuations, broken down by dose arm (i.e. Low vs. Medium vs. High vs. Placebo), and further broken down by relatedness to Posiphen (Definitely Related, Probably Related, Possibly Related, Unlikely Related, Unrelated)
| events | Low Dose | Medium Dose | High Dose | Placebo |
|---|---|---|---|---|
| Definitely Related | 0 | 0 | 0 | 0 |
| Probably Related | 0 | 1 | 0 | 0 |
| Possibly Related | 1 | 0 | 0 | 2 |
| Unlikely Related | 2 | 3 | 0 | 2 |
| Unrelated | 9 | 11 | 0 | 6 |
| Total | 12 | 15 | 0 | 10 |
Mean plasma concentrations of levels of posiphen tartrate, N1 desmethyl posiphen, and N8 desmethyl Posiphen metabolite were determined for each of the three dose cohorts (Low Dose, Medium Dose, High Dose) by a protein precipitation extraction method using a high performance liquid chromatographic mass spectrometric detection method, with a linear weighted regression to determine their concentrations.
| ng/mL | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Posiphen | 7.16 ± 4.25 | 9.51 ± 5.77 | 12.01 ± 0 |
| N1 metabolite | 1.29 ± 0.77 | 3.02 ± 1.4 | 2.51 ± 0 |
| N8 metabolite | 2.25 ± 1.36 | 5.04 ± 1.8 | 3.35 ± 0 |
Mean CSF concentrations of levels of posiphen tartrate, N1 desmethyl posiphen, and N8 desmethyl Posiphen metabolite were determined for each of the three dose cohorts (Low Dose, Medium Dose, High Dose) by a protein precipitation extraction method using a high performance liquid chromatographic mass spectrometric detection method, with a linear weighted regression to determine the concentrations.
| ng/mL | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| Posiphen | 0.46 ± 0.3 | 0.73 ± 0.52 | 0.71 ± 0 |
| N1 metabolite | 0.02 ± 0.04 | 0.28 ± 0.3 | 0 ± 0 |
| N8 metabolite | 0.35 ± 0.26 | 0.77 ± 0.43 | 0.15 ± 0 |
The fractional synthesis rate (FSR) of Aβ40 was measured in the CSF using the SILK™ technique. FSR is a measure of the rate of Aβ synthesis in the brain. During 13C6-leucine infusion, 13C6-leucine is incorporated into newly synthesized proteins throughout the body, including the brain, in proportion to the available 13C6-leucine. This FSR is calculated as the rate of change of the ratio of 13C6-leucine-labeled Aβ proteins to unlabeled Aβ proteins in the lumbar CSF between 6 to 16 hours, normalized to the ratio of labeled to unlabeled leucine amino acid in plasma. It is reported as a fraction of 13C6-leucine-labeled to unlabeled Aβ proteins per hour. The ratio of Aβ in CSF containing 13C6-leucine to that containing unlabeled leucine is measured using mass spectrometry.
| fraction labeled:unlabeled Aβ40 per hr | Low Dose | Medium Dose | High Dose | Placebo |
|---|---|---|---|---|
| Fractional Synthesis Rate of Aβ40 in CSF Using the SILK™ Technique With Multiple Doses of Posiphen | 0.0405 (0.0298 to 0.0431) | 0.0400 (0.0373 to 0.0511) | 0.0206 (0.0206 to 0.0206) | 0.0375 (0.0319 to 0.0449) |
Feasibility of CSF Catheter Study with SILK™ Technology was determined by comparing the total number of participants enrolled, randomized and treated with study drug in the trial to the total number of participants who completed the CSF Catheter Study across all participating sites.
| Participants | Active Treatment Arms | Placebo Arm |
|---|---|---|
| Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate Rates of Enrollment | 10 | 5 |
The % of cerebrospinal fluid samples with sufficient volume for testing will be determined across study participants during the SILK sampling procedure
| percentage of CSF samples | All Randomized Participants Who Completed 36 Hour Confinement Visit (n=15) |
|---|---|
| Feasibility of CSF Catheter Study With SILK™ Technology to Evaluate %CSF Samples With Enough Volume for Testing | 81.75 |
Research satisfaction will be evaluated by qualitative response to 14 questions asked to participants about their experience with the study procedures. Responses will be grouped and reported by common themes
| percentage of participants | All Randomized Participants |
|---|---|
| Rated "Excellent" for quality of tests and attention received during participation in the study. | 94 |
| Reported "Almost all of my expectations have been met" by the research program. | 81 |
| Reported "Yes, definitely" they would recommend this research program to a friend. | 94 |
| Reported "Yes, definitely" they would choose to participate again. | 87.5 |
| Reported "Volunteering" as what they liked best about the study. | 31 |
| Reported "Time Commitment" as what they liked least about the study. | 31 |
| Reported "Yes", the 36 hour catheter procedure was done. | 100 |
| Reported "No" adverse events were associated with the 36hr catheter procedure. | 73 |
| Reported "Excellent" as the quality of the 36hr catheter procedure and attention they received. | 80 |
| Reported the catheter procedure was "almost all of what I expected." | 67 |
| Reported they liked best was "participating in cutting edge research and interacting with the team". | 100 |
| Reported "Other" as what they liked least about the 36hr catheter procedure. | 47 |
| Reported "Other" as what they would change about the 36hr catheter procedure. | 71 |
| Reported they would change the number of visits. | 50 |
Aβ38, Aβ40, Aβ42, sAPPα, sAPPβ, and T-Tau were sampled at Screening and at the start of the confinement visit. Results of these measures were reported as a least square means, calculated as the change between the measured values at the start of the confinement visit and Screening in ng/mL.
| ng/mL | Active Treatment Arms | Placebo Arm |
|---|---|---|
| Aβ38 | 0.391 ± 0.173 | 0.593 ± 0.199 |
| Aβ40 | 1.73 ± 0.998 | 3.13 ± 1.151 |
| Aβ42 | 0.107 ± 0.0653 | 0.211 ± 0.0753 |
| sAPPα | 6.49 ± 5.75 | -3.5 ± 9.07 |
| sAPPβ | 19.1 ± 16.8 | -28.6 ± 26.5 |
| Total Tau | 186.4 ± 79.1 | 53.7 ± 124.9 |
The short-term effects of Posiphen on mental status will be measured using the Mini-Mental State Examination (MMSE). The MMSE is a brief, global cognitive measure that includes orientation, memory, attention, concentration, naming, writing, repetition, comprehension, and construction. The total score ranges from 0 (worst) to 30 (best performance). Results of the MMSE for this trial were reported as a raw change score, calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) and where negative values are worse and positive values are better.
| score on a scale | Low Dose | Medium Dose | High Dose | Placebo |
|---|---|---|---|---|
| Assessment of Mental Status Effects | -1.4 ± 0.89 | 1.2 ± 2.39 | -1 ± 0 | 1.14 ± 2.12 |
The Neuropsychiatric Inventory (NPI) was used to measure the frequency and severity of neuropsychiatric symptoms. On this scale frequency ratings range from 0 (no symptoms) to 4 (very frequently, once or more per day or continuously). Severity ratings range from 0 (no severity) to 3 (severe). The score for each of 12 symptoms measured in the scale is the product of severity and frequency within that symptom. The total score for the NPI is the sum of all 12 symptom item scores, for a highest possible total score of 144 in individuals with maximal symptoms, and a lowest possible total score of zero (0) in fully asymptomatic individuals. Lower scores are better and higher scores indicate more neuropsychiatric symptoms. Results are calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) with negative scores being better and positive scores being worse.
| score on a scale | Low Dose | Medium Dose | High Dose | Placebo |
|---|---|---|---|---|
| Assessment of Neuropsychiatric Effects | -2.6 ± 2.88 | 3.4 ± 8.47 | -9 ± 0 | -3.86 ± 8.09 |
The short-term effects of Posiphen on cognition were measured using the The Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12). The ADAS-Cog is a structured scale that evaluates memory (word recall, word recognition), reasoning, language (naming, comprehension), orientation, ideational praxis and constructional praxis. The test is scored in terms of errors, with higher scores reflecting poorer performance and greater impairment. Total ADAS-Cog12 scores can range from 0 to 80, with lower scores being better and higher scores being worse. Results of the ADAS-Cog12 for this trial are reported as a raw change score, calculated as the change between the total scores at two evaluation time points (Baseline, Pre-Confinement Visit) with negative scores being better and positive scores being worse.
| score on a scale | Active Treatment Arms | Placebo Arm |
|---|---|---|
| Assessment of Cognitive Effects | -0.55 ± 6.04 | -1.57 ± 5.19 |
Collected over From Randomization through Study Day 25.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Medium Dose | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| High Dose | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Placebo | 0/7 (0%) | 0/7 (0%) | 4/7 (57.1%) |
| Event | Low Dose | Medium Dose | High Dose | Placebo |
|---|---|---|---|---|
| headacheNervous system disorders | 1/5 | 2/5 | 0/1 | 3/7 |
| medical device complicationGastrointestinal disorders | 0/5 | 2/5 | 0/1 | 0/7 |
| pain in extremityMusculoskeletal and connective tissue disorders | 2/5 | 0/5 | 0/1 | 0/7 |
| post lumbar puncture syndromeInjury, poisoning and procedural complications | 2/5 | 1/5 | 0/1 | 1/7 |
| tremorNervous system disorders | 0/5 | 0/5 | 0/1 | 2/7 |
| agitationPsychiatric disorders | 0/5 | 1/5 | 0/1 | 0/7 |
| back painMusculoskeletal and connective tissue disorders | 1/5 | 0/5 | 0/1 | 0/7 |
| coughRespiratory, thoracic and mediastinal disorders | 0/5 | 1/5 | 0/1 | 0/7 |
| diarrhoeaGastrointestinal disorders | 0/5 | 1/5 | 0/1 | 0/7 |
| fatigueGeneral disorders | 1/5 | 0/5 | 0/1 | 0/7 |
| Age, Categorical(Participants) | Low Dose | Medium Dose | High Dose | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 2 | 1 | 1 | 5 |
| >=65 years | 4 | 3 | 0 | 6 | 13 |
| Sex: Female, Male(Participants) | Low Dose | Medium Dose | High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 5 | 0 | 0 | 3 | 8 |
| Male | 0 | 5 | 1 | 4 | 10 |
| Race/Ethnicity, Customized(Participants) | Low Dose | Medium Dose | High Dose | Placebo | Total |
|---|---|---|---|---|---|
| White | 5 | 5 | 1 | 6 | 17 |
| Unknown, Not Reported | 0 | 0 | 0 | 1 | 1 |
| Not-Hispanic or Latino | 5 | 5 | 1 | 6 | 17 |
| Hispanic or Latino | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Low Dose | Medium Dose | High Dose | Placebo | Total |
|---|---|---|---|---|---|
| United States | 5 | 5 | 1 | 7 | 18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this research will be shared with other researchers pursuant to the 02/26/2003 "NIH Final Statement on Sharing Research Data". The ADCS through its Data and Sample Sharing Committee (DSSC) will receive requests for sample and data sharing. The ADCS grants access to de-identified data to qualified scientists who complete the request process and agree to conditions in an ADCS/UCSD Data Use Agreement (DUA) and the ADCS Publications Policy. After approval and receipt of the fully executed DUA, applicants are authorized to acquire data. Non-compliance with the DUA, including the requirement to provide requested updates will jeopardize further access to data. The same process and Committee reviews and approves biosample requests. If a request for biosample sharing is approved, a Material Transfer Agreement (MTA) will be negotiated between UCSD/ADCS and the requesting researcher or organization.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: 01 August 2023
Access criteria: Data requestors must complete an ADCS Data and Sample Sharing request form which will be reviewed by the ADCS DSSC. Upon approval, requestors must complete a Data Use Agreement (DUA) prior to accessing the data.
Data sharing details ↗ · www.adcs.org
Ran from Mar 2017 to primary completion in Dec 2021, 57 months.
Results were first posted in May 2023, 1 year 4 months after primary completion.
Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 57 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Buntanetap
Annovis Bio Inc.